Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/10/16Seres Therapeutics Reports Third Quarter 2016 Financial Results and Provides Operational Progress Update
- Analyses of SER-109 Phase 2 results on track for completion by year end; Company intends to discuss proposed future SER-109 clinical development plans with the FDA - - Pipeline progress with SER-287 and SER-262 Phase 1b study execution; data read-outs continue to be expected in 2017 - - New microbiome patent strengthens the Company’s intellectual property estate - - Conference call at 8:00 a.m. ET today - ... 
 Printer Friendly Version
11/04/16Seres Therapeutics to Host Third Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2016 at 8:00 a.m. ET to discuss third quarter 2016 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (internatio... 
 Printer Friendly Version
08/11/16Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
- Comprehensive review of initial SER-109 Phase 2 study data underway - - Strong cash position to support operations well into 2018, and through the anticipated Phase 1b study read-outs for SER-287 and SER-262 – - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2016-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported second quarter... 
 Printer Friendly Version
08/05/16Seres Therapeutics to Host Second Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on August 11, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 5, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2016 at 8:30 a.m. ET to discuss second quarter 2016 results. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160805005067/en/ To access t... 
 Printer Friendly Version
07/29/16Seres Therapeutics Announces Interim Results from SER-109 Phase 2 ECOSPOR Study in Multiply Recurrent Clostridium difficile Infection
- Primary efficacy endpoint was not achieved - - Conference call at 8:30 AM ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced interim 8-week results from the ongoing SER-109 Phase 2 ECOSPORTM clinical study for the prevention of multiply recurrent Clostridium difficile infection (CDI). The study’s primary endpoint of r... 
 Printer Friendly Version
07/12/16Seres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, and Emulate, Inc., a private company commercializing the Organs-on-Chips technology, today announced a new collaboration. Under the terms of the agreement, Seres and Emulate will work to further advance Emulate’s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human i... 
 Printer Friendly Version
07/07/16Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-262 for Primary Clostridium difficile Infection
- First ever clinical study of a synthetic microbiome therapeutic - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 7, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has initiated a Phase 1b clinical trial evaluating SER-262 in patients with primary Clostridium difficile infection (CDI). SER-262 is an Ecobiotic® rationally-designed, fermented microbiome therapeutic derived by a manufacturing p... 
 Printer Friendly Version
06/22/16Seres Therapeutics Announces Collaboration with Massachusetts General Hospital to Identify Microbiome Therapeutics for Obesity and Metabolic Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 22, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced a collaboration with Massachusetts General Hospital (MGH) of the Harvard Medical School to support translational research focused on identifying microbiome therapeutics for obesity and metabolic syndrome. Under the terms of the agreement, Seres will help fund a placebo-controlled, pr... 
 Printer Friendly Version
06/20/16Seres Therapeutics Presents New Data at ASM Microbe 2016, including Characterization of SER-262, the Rationally-Designed, Fermented Microbiome Therapeutic Candidate for Primary Clostridium difficile Infection
- Initiation of a SER-262 Phase 1b study, a first ever for a synthetic microbiome therapeutic, is expected to begin in mid-2016 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced the presentation of new data on its lead SER-109 Phase 2 microbiome program for multiply recurrent Clostridium difficile infection (CDI), and its SER-262 prec... 
 Printer Friendly Version
06/06/16Seres Therapeutics Announces Research Collaboration with Mayo Clinic to Identify Microbiome Therapeutics for Primary Sclerosing Cholangitis, Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has initiated a sponsored research agreement with Mayo Clinic’s Center for Individualized Medicine focused on identifying new microbiome therapeutic candidates for liver diseases. Under the terms of the agreement, Mayo Clinic Professor Nicholas F. LaRusso, M.D., a leading rese... 
 Printer Friendly Version
06/02/16Seres Therapeutics to Present at Goldman Sachs 37th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 7 at 9:20 a.m. PT. Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available... 
 Printer Friendly Version
05/17/16Seres Therapeutics to Present at the 2016 UBS Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the UBS Global Healthcare Conference on Tuesday, May 24. The presentation will take place at the Grand Hyatt Hotel in New York, NY at 8:30 a.m. ET. Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation wi... 
 Printer Friendly Version
05/16/16Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update
SER-109 Phase 2 study enrollment complete; results expected in mid-2016 Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications $120 million upfront payment obtained from Nestlé Health Science CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported ... 
 Printer Friendly Version
05/16/16Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Thomas J. DesRosier as Chief Legal Officer and Executive Vice President. DesRosier will be responsible for global legal operations, as well as corporate compliance and quality assurance. He will also act as Secretary for Seres’ Leadership Team and its Board of Directors. “... 
 Printer Friendly Version
05/12/16Seres Therapeutics Announces Collaboration with University of Pennsylvania Researchers to Support the Development of Microbiome Therapeutics for Rare Genetic Metabolic Diseases and Inflammatory Bowel Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a multi-year collaboration with leading microbiome clinical-scientists from the University of Pennsylvania (Penn) to support the development of novel treatment approaches for certain rare genetic metabolic diseases including urea cycle disorders, and inflammatory bowel disea... 
 Printer Friendly Version
05/12/16Seres Therapeutics Announces Broad Agreement with Memorial Sloan Kettering Cancer Center to Develop Microbiome Therapeutics for Hematopoietic Stem Cell Transplantation and Immuno-Oncology Treatment
- Agreements provide IP license bolstering Company's strong patent portfolio - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that it has entered into a strategic, multi-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK). The collaboration will support the translation of novel discoveries from MSK la... 
 Printer Friendly Version
05/09/16Seres Therapeutics to Host First Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on May 16, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Monday, May 16, 2016 at 8:30 a.m. ET to discuss first quarter 2016 results. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 83... 
 Printer Friendly Version
05/04/16Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2016-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it has entered into two separate research collaborations with leading academic groups to support Seres’ ongoing development of the first potential microbiome therapeutics for inflammatory bowel disease (IBD). Under the agreements, Seres will collaborate with leading researchers at the... 
 Printer Friendly Version
05/03/16Seres Therapeutics to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 3, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas on Tuesday, May 10. The presentation will take place at the Encore at Wynn Las Vegas at 10:40 a.m. PDT. Live audio webcast will be available under the Investors and Media section of Seres’ web... 
 Printer Friendly Version
05/02/16Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection
Phase 2 data expected in mid-2016 New SER-109 Expanded Access Program initiated at Phase 2 clinical sites CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, announced today that the target enrollment of 87 patients has been achieved for its ongoing SER-109 Phase 2 clinical study. SER-109 is an oral, potential first-in-field microbiome thera... 
 Printer Friendly Version
03/14/16Seres Therapeutics to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 14, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Barclays Global Healthcare Conference on Thursday, March 17. The presentation will take place at 1:05 p.m. EDT. Live audio webcast of the presentation will be available under the Investors and Media section of Seres’ website. A replay of the presentation will b... 
 Printer Friendly Version
03/02/16Seres Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9. The presentation will take place in the Provincetown Room at the Boston Marriott Copley Place at 10 a.m. EST. Live audio webcast will be available under the Investors and Media ... 
 Printer Friendly Version
02/25/16Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update
Company highlights progress in commercial preparedness, pipeline expansion Strong financial position; existing cash expected to support operations well into 2018 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2016-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2015. ... 
 Printer Friendly Version
02/16/16Seres Therapeutics to Host Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on February 25, 2016
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Thursday, February 25, 2016 at 8:30 a.m. EST to discuss fourth quarter and full year 2015 financial results. To access the conference call, please dial 888-834-1266 (domestic) or 440-996-5713 (international) and re... 
 Printer Friendly Version
02/09/16Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases
87 percent of patients with recurrent C. difficile infection met primary endpoint; 97 percent achieved clinical cure CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 9, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced that positive results from the Phase 1b/2 study of SER-109 in recurrent Clostridium difficile infection (CDI) were published today in The Journal of Infectious Diseases. Th... 
 Printer Friendly Version
01/29/16Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will participate in two investor conferences in February: Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday, Feb. 2, 2016 in New York, NY. Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in New York, NY. ... 
 Printer Friendly Version
01/11/16Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science for Microbiome-Based Clostridium difficile and Inflammatory Bowel Disease Therapies in Markets Outside of North America
Nestlé Health Science’s global reach and gastroenterology focus expected to support development and commercialization Deal provides $120 million upfront with potential total value of over $1.9 billion CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, announced today that it has entered into an agreement with Nestlé Health Science for the... 
 Printer Friendly Version
01/06/16Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President. In this newly created role, Hashad will be responsible for all activities related to the anticipated commercialization of the company’s products in development, including SER-109, which is currently in a ... 
 Printer Friendly Version
01/06/16Seres Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres, will present a company overview at the 34th annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, Jan. 13, at 3 p.m. PT at the Westin St. Francis Hotel. Live... 
 Printer Friendly Version